I’m excited to join fellow experts and Shirley @leung at @BostonGlobe Media’s Future of Medicine Summit to discuss how cancer vaccines are rewriting the rules of treatment – exploring how personalized mRNA vaccines are moving from moonshot ideas to real clinical trials with real patients and real benefits! Join us on September 15 for a day of thought-provoking conversations about what’s next in healthcare. Learn more and register at Globe.com/futureofmedicine. #FutureofMed2026 @DanaFarber @DanaFarber_GU @DanaFarberNews @OnlyInBOS @ScienceinBoston @harvardmed @TheVinodLab #MichelleBrown

We are hiring for a new pilot initiative at @MSKCancerCenter – The Theory Group. The Group is centered around tumor-immune interactions and the notion that, in our post-AI moment, theoretical approaches from physics, math, quantitative ecology and computer science can unlock fundamental questions with major translational impact. We are hiring Fellows for this effort. Drawing inspiration from groups like the Theoretical Division at Bell Labs, the idea is that by working with the amazing translational and basic research investigators around cancer and the immune system, real advances can be made that would not occur anywhere else. I am convinced we are at that moment here. TLDR – if you are a postdoc with a background above who has worked with biological data and wishes to apply for this fellowship, please check out the link below. There will be organized chalk talks, but independent research will be valued. msk.wd108.myworkdayjobs.com/…

🔆🔆🔆Matching T-cell receptors (TCRs) to their cognate peptides presented on MHC molecules (pMHCs) from sequence data alone is one of the most important unsolved problems in computational immunology. I've been presenting this work for over a year and am excited to finally share the preprint and public code. A transformative collaboration for our lab with @quaidmorris (see tweetorial 👇👇with links). Led by first authors @Olga_Lyu, Jonathan Levine & Melissa Pathil, with S. Martis, A. Streltsov, Z. Sethna, Y. Elhanati (@elhanati_yuval), Vinod Balachandran (@TheVinodLab)!!! @MSKCancerCenter

Donna was diagnosed with pancreatic cancer at age 66 when she and her husband were visiting one of their daughters in Australia. When they returned to the U.S., they immediately came to MSK for care, where she learned she was eligible for an investigational vaccine trial, to prevent pancreatic cancer from returning after surgery. MSK hepatopancreatobiliary surgeon Dr. @Jeffrey_Drebin, physician-scientist @TheVinodLab, and medical oncologist @EileenMOReilly walked Donna through each step. “They described how they would take part of my tumor to make a personalized vaccine, and it sounded amazing,” Donna says. “My husband and I had a moment of concern about delaying chemotherapy, but all the doctors made me feel so comfortable that we took the leap of faith and said, ‘Go for it.’” Over the next few months, Donna received an immunotherapy drug and eight doses of the vaccine, followed by chemotherapy, and then a final vaccine dose. Today, Donna is 72 and recently celebrated her 50th anniversary with her husband in Sicily and spends as much time as she can with her daughters and six grandchildren. Learn more about this clinical trial, presented at the 2026 American Association for Cancer Research Annual Meeting: bit.ly/3QuIiaL #AACR26

Long term follow up of a phase 1 trial of an mRNA tumor vaccine shows that 7/8 patients with pancreatic cancer, who mounted an immune response to the vaccine, are still alive 6 years later. This is breathtaking data and shows the promise of mRNA vaccines. nbcnews.com/health/cancer/pa…

Over the last decade, computational oncologist Dr. @bengrbm has tried to shed light on the innate immune system and how it affects cancer cells as they evolve. One important aspect is a phenomenon called “viral mimicry,” caused by repetitive DNA sequences. Now Dr. Greenbaum’s lab, in collaboration with an international team of researchers, has developed a mathematical model to quantify viral mimicry based on methods from statistical physics, machine learning, and the dynamics of evolution. “A better understanding of what activates the innate immune system can help us figure out how to improve immunotherapies,” says Dr. Greenbaum. Learn more about this research: bit.ly/4h1BjPG